Breakthrough hepatitis C medicines remain in regulatory limbo

Breakthrough hepatitis C medicines remain in regulatory limbo

Over the last decade the treatment of hepatitis C, a virus that can infect and damage the liver, has been revolutionised by a new class of medicines called direct acting antivirals. Catherine Tomlinson investigates the regulatory obstacles that are limiting access to these breakthrough medicines in South Africa.

Read More